fragment 176-191 (AOD9604): the lipolytic tail of growth hormone

fragment 176-191, the research codename AOD9604, is a synthetic 16-amino-acid peptide corresponding to residues 176 through 191 of human growth hormone. it was designed at Monash University and developed by Metabolic Pharmaceuticals to isolate the lipolytic tail of GH from the parts of the molecule responsible for growth-promotion and insulin antagonism. it is not an FDA-approved drug. it later took a different regulatory route as a food-supplement ingredient.

what is fragment 176-191?

fragment 176-191 is the last 16 amino acids of the 191-residue human growth hormone molecule, with a tyrosine added to the front. that small tail had been shown decades earlier to carry most of the fat-burning activity of GH in animal models, without the parts of the molecule needed to drive growth or interfere with insulin.

full-length human growth hormone is 191 amino acids long. early biochemical work by Bornstein and colleagues, and later by Ng and Bornstein, mapped a "lipolytic domain" inside the C-terminal tail of the molecule. AOD9604 took that mapping seriously and synthesised the 176-191 segment as a stand-alone peptide, with a tyrosine residue added at the N-terminus to aid manufacturing and stability. the result is a small, fast-clearing hexadecapeptide rather than a full hormone [1].

the developer was Metabolic Pharmaceuticals (later Calzada), an Australian biotech spun out of Monash University. AOD9604 sat for years in the obesity pipeline alongside other GH-axis tools before the program shifted from a prescription drug to a food-supplement ingredient after the Phase 2b results came in.

how does it work?

in preclinical models the fragment promotes lipolysis (the release of stored fat) and inhibits lipogenesis (the storage of new fat), apparently without raising IGF-1 or producing the insulin-antagonist effects that full growth hormone causes. the downstream mechanism appears to involve beta-3 adrenergic signalling in adipocytes rather than the classical GH receptor pathway.

the most informative mechanistic work came from Heffernan and colleagues in Endocrinology in 2001, who compared chronic treatment with intact human GH and with AOD9604 in obese mice and in beta-3 adrenergic receptor knockout mice. intact GH raised IGF-1 and produced insulin resistance, as expected. AOD9604 produced weight loss and improved lipid handling without raising IGF-1, and the fat-loss effect was sharply blunted in animals that lacked the beta-3 receptor [2]. a companion paper by Heffernan in the International Journal of Obesity reported that AOD9604 increased fat oxidation and reduced body weight in obese rodents on chronic dosing [3].

the mechanistic story is therefore a separation: the C-terminal tail seems to carry signals that mobilise fat without engaging the GH receptor in the same way as the full hormone. that is what made it interesting as a potential drug, and it is also why community marketing tends to claim a "clean" fat-loss profile. the caveat is that almost all of this mechanistic work is preclinical.

what does the human evidence show?

between roughly 2001 and 2007, AOD9604 was tested in a Phase 2 program in obese adults that included two oral Phase 2b trials enrolling several hundred subjects. the separation from placebo was small (on the order of a kilogram or two over 12 weeks), did not meet the efficacy threshold for drug registration, and the development program was discontinued as a prescription drug.

the Phase 2b oral program tested several doses of AOD9604 against placebo in clinically obese adults across multiple centres. The 1 mg dose arm produced the largest mean weight loss in the published summary, on the order of a couple of kilograms over 12 weeks, with placebo subjects losing under a kilogram. all dose groups were well tolerated and there was no detectable signal on fasting glucose, insulin sensitivity, or IGF-1, which mirrored the preclinical separation from full GH [4]. the absolute magnitude of weight loss, however, was not commercially or clinically competitive with the obesity pipeline that was emerging at the time and the program shifted strategy.

a 2015 metabolism and detection study by Cox and colleagues confirmed that AOD9604 is detectable in human urine using mass spectrometry methods relevant to anti-doping, which is consistent with WADA's treatment of the fragment as a banned substance under category S2 [5]. a small intra-articular study by Kwon in a rabbit osteoarthritis model later suggested possible chondroprotective effects when AOD9604 was injected into the joint with or without hyaluronic acid, which has been used by marketers to support claims for joint healing in humans, but no comparable human RCT exists [6].

a 2014 nutraceutical-positioned safety and metabolism paper by Stier and colleagues summarised the broader human exposure data set across the Phase 2 program (approximately 900 adult participants by the developer's count), reporting no evidence of immunogenicity, no impact on glucose handling, and a tolerability profile that supported a GRAS (generally recognized as safe) self-affirmation for use in dietary supplements [7]. the honest summary of the human evidence is: safe in the doses studied, real but modest separation from placebo on weight, and not strong enough to clear the bar for a prescription anti-obesity drug.

regulatory status

AOD9604 has never been approved by the FDA, the EMA, or the TGA as a drug. its current US market presence is on the dietary-supplement side, after a GRAS self-affirmation that supports its use as a food ingredient. it is also on the WADA prohibited list in sport. for compounded peptide use under a healthcare provider, AOD9604 is also among the substances flagged by the FDA's compounding category-2 review.

the original drug-development sponsor abandoned its prescription pathway after the Phase 2b obesity program. the fragment then re-emerged through a US GRAS self-determination as a dietary-supplement ingredient, a pathway that does not require FDA pre-market approval and does not involve a Phase 3 efficacy demonstration. consumers should read GRAS as a food-safety designation, not as a drug-efficacy verdict.

in sport, AOD9604 sits under WADA category S2.5 (peptide hormones, growth factors, related substances and mimetics) and is prohibited at all times in and out of competition. in the compounded-peptide market, the FDA's 503A bulks list review placed AOD9604 in the category-2 bucket flagging safety concerns about non-pharmaceutical-grade compounded use, alongside several other GH-axis peptides.

safety profile

across the published Phase 2 program AOD9604 was well tolerated, with no detected effect on glucose homeostasis, no IGF-1 elevation, no immunogenicity signal, and an adverse-event profile similar to placebo. long-term human safety data beyond the trial durations and outside healthy obese adults are limited.

in the published Phase 2 trials and the pooled safety analyses, the adverse-event rate did not separate meaningfully from placebo, anti-AOD9604 antibodies were not detected, fasting glucose and insulin sensitivity were preserved, and IGF-1 did not climb [7]. this is the cleanest part of the AOD9604 story and is the reason the molecule survived as a supplement ingredient even after its drug-development arc stalled.

the gaps to teach honestly are: there are no controlled long-term safety studies beyond the trial windows, no published RCT data in lean adults, no published efficacy data in joint, skin, or recovery indications despite heavy community marketing in those niches, and no controlled human data for injectable use of AOD9604 (the oral route was the one tested in Phase 2).

where it fits in peptide research

fragment 176-191 is the smallest and most narrowly designed member of the GH-axis fat-loss family. the better-studied molecules in that family act upstream on GH release rather than downstream on adipose. understanding the difference is the most useful framing of where AOD9604 sits.

the natural comparison is tesamorelin, an FDA-approved GHRH analog that raises endogenous growth hormone pulses and IGF-1, and which has Phase 3 evidence for visceral-fat reduction in HIV-associated lipodystrophy. tesamorelin and AOD9604 are mechanistically opposite ends of the same axis: tesamorelin amplifies the full hormone upstream, fragment 176-191 attempts to extract one downstream signal without the rest of the hormone.

on the IGF-1 splice-variant side of the same family, MGF and PEG-MGF aim at muscle satellite-cell activation rather than adipose. those are also research-only peptides without FDA-approved products. for the broader GLP-1 family that does have approved fat-axis drugs, see semaglutide and tirzepatide.

if you want a structured introduction to how the GH axis interacts with the rest of peptide biology, the free peptides and your body module is the place to start, and the FDA-approved peptides reference covers what "approved" actually means and how AOD9604's GRAS status differs from a drug approval.